As the ADC landscape becomes busier and more crowded around validated Topo1 and MMAE payloads, the need for differentiated mechanisms is vital to ensure future conjugates can overcome anticipated resistance and deliver patient benefit

Join this workshop session to navigate the different avenues of novel payload development, assessing the emerging performance of cytotoxic, non-cytotoxic and dual payload approaches to discuss and debate the next payload wave to replace topoisomerase inhibitors

Workshop highlights include:

• Discussing the crucial need for novel ADC payloads in the face of crowded clinical landscapes and future patient resistance mechanisms
• Weighing up risk level against novelty of mechanism when approaching novel payload development: What linker payloads are showing the most promise so far?
• Evaluating the opportunity for dual payload ADCs and combination therapies to combat patient resistance